Surfer_02.jpg
BKGD images Orange1.jpg
Scientific BKGD_01.jpg
BKGD images Blue.jpg
Scientific BKGD_02.jpg
BKGD images Orange1.jpg
Scientific BKGD_03.jpg
BKGD images Gray.jpg
BKGD images Orange1.jpg
Surfer_02.jpg

Life Changing


SCROLL DOWN

Life Changing


Life Changing:
Monoclonal Microbials

BKGD images Orange1.jpg

The Science


The Science


Evelo's vision is to improve the lives of patients with serious diseases through the development of a broadly applicable new modality of medicines – monoclonal microbials

Monoclonal Microbials


Monoclonal Microbials


 

Monoclonal microbials act through the gut to modulate biology that impacts many diseases

Humans have evolved over millennia with the microbes in and on our bodies. These microbes play a vital role in developing and directing immune and biological responses.

Evelo is harnessing the therapeutic potential of specific strains of naturally occurring microbes and developing them as a new class of medicines, monoclonal microbials.

We have validated that orally delivered monoclonal microbials modulate immunological and biological effects throughout the body after initial interactions with human cells in the gut.

Evelo is pioneering the development of this new class of medicine for the treatment of autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer.

 

Oncology Colon Cancer, Lung Cancer, Melanoma, Renal Cancer, Bladder Cancer

Immuno-Inflammatory Disease Psoriasis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Atopic Dermatitis, Food Allergy, Type I Diabetes

Neuro-Inflammation/Degeneration Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease

Evelo_Lumin_Icon2.png

Neuro-CNS Autism, Anxiety, Depression

Metabolism Malnutrition, Type II Diabetes, Obesity, Nonalcoholic Fatty Liver Disease, Heart Disease

Vaccines Oral vaccines for autoimmune disease, infectious disease, and cancer; conditioning responses to current vaccines

 
Scientific BKGD_01.jpg

Our Approach


Our Approach


Our platform integrates expertise in microbiology, immunology, pharmacology and computational biology.

We find and select naturally occurring monoclonal microbials for therapeutic use.

Our monoclonal microbials are developed with expertise in experimental medicine, formulation, delivery, process development and manufacturing.

Immune System


Immune System


 

Monoclonal microbials and the immune system

We have discovered and are developing specific monoclonal microbials that modulate systemic biology.

These single strains impact multiple immunomodulatory pathways:

Mechanisms clinically relevant to treating cancer

  • Activation of dendritic cell subtypes, activation of pro-inflammatory macrophages and infiltration of T cells to the tumor microenvironment

Mechanisms clinically relevant to treating autoimmune and inflammatory diseases

  • Induction of regulatory T cell activity, inhibition of inflammatory cytokines and induction of regulatory dendritic cells
 
BKGD images Blue.jpg

Pipeline


Pipeline


Pipeline

We are advancing multiple monoclonal microbials with differentiated immunomodulatory activities through pre-clinical development and will start several clinical studies across oncology and immunoinflammatory diseases in 2018.

Scientific BKGD_02.jpg

What Matters


What Matters


Every life matters and we are driven by the mission to provide broad access to important new medicines.

Current Healthcare


Current Healthcare


 

Current healthcare doesn’t work for everyone

Biotech has helped many people through great science innovation in areas including monoclonal antibodies and targeted anti viral and oncology therapies.

Despite great success in treating many diseases, current healthcare is limited.

Currently, we treat late stages of diseases in a small portion of the world’s population with high cost drugs that have many side effects.

We are committed to dramatically improving healthcare

Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development.

By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, we can improve the speed, cost and probability of drug discovery and development.

Evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials.

 
BKGD images Orange1.jpg

Our Team


Our Team


Evelo is led by one of the most
experienced teams in the industry.

Our leadership team has founded, led and grown some of the most important and transformative platform biotech companies and impacted many lives through the development of important medicines.

Leadership


Leadership


 

Leadership

  • Simba Gill
    CEO
  • Mark Bodmer
    President of R&D, Chief Scientific Officer
  • William Devaul
    Head of Intellectual Property
  • Humphrey Gardner
    Chief of Medical Oncology
  • Jennifer Glennon
    Head of Finance and Operations
  • Brian Goodman
    Head of Technology and Innovation
  • Andrea Itano
    Head of Immuno-inflammatory Diseases
  • Jackie Papkoff
    Head of Oncology Research
  • Kareem Reda
    Head of BD & Corporate Strategy
  • Hank Wu
    Head of Data Science
  • Chun Zhang
    Head of Process Development and Manufacturing

Board of Directors

  • Noubar Afeyan
    Chairman
  • Simba Gill
    CEO
  • David Berry
    Director
  • David Epstein
    Director
  • Theo Melas-Kyriazi
    Director
  • David Perry
    Director
  • Stelios Papadopoulos
    Special Board Advisor

 
Scientific BKGD_03.jpg

Investors


Investors


Investors

Evelo was founded by Flagship Pioneering, which conceives, creates, 
resources and develops first-in-category life sciences companies.

Google Ventures, Celgene, Mayo Clinic and Alexandria Venture Investments
have joined Flagship Pioneering as investors in Evelo.

Investor Logos


Investor Logos


BKGD images Gray.jpg

Destination


Destination


The destination for pioneers and adventurers

If you want to join an exceptional team and culture that is committed to changing the world, let us know.

BKGD images Orange1.jpg

Contact


Contact


Contact

620 Memorial Drive | Suite 200 West | Cambridge, MA, 02139 USA

info@evelobio.com

+ 1 (617) 577-0300